Literature DB >> 26105022

Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol.

Dragan A Stojanov1,2, Aleksandra Aracki-Trenkic3, Slobodan Vojinovic4,5, Daniela Benedeto-Stojanov6, Srdjan Ljubisavljevic7,8.   

Abstract

OBJECTIVE: To evaluate correlation between cumulative dose of gadobutrol and signal intensity (SI) within dentate nucleus and globus pallidus on unenhanced T1-weighted images in patients with relapsing-remitting multiple sclerosis (RRMS).
METHODS: Dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios, and renal and liver functions, were evaluated after multiple intravenous administrations of 0.1 mmol/kg gadobutrol at 27, 96-98, and 168 weeks. We compared SI ratios based on the number of administrations, total amount of gadobutrol administered, and time between injections.
RESULTS: Globus pallidus-to-thalamus (p = 0.025) and dentate nucleus-to-pons (p < 0.001) SI ratios increased after multiple gadobutrol administrations, correlated with the number of administrations (ρ = 0.263, p = 0.046, respectively) and depended on the length of administration (p = 0.017, p = 0.037, respectively). Patients receiving gadobutrol at 27 weeks showed the greatest increase in both SI ratios (p = 0.006; p = 0.014, respectively, versus 96-98 weeks). GGT increased at the end of the study (p = 0.004).
CONCLUSION: In patients with RRMS, SI within the dentate nucleus and globus pallidus increased on unenhanced T1-weighted images after multiple gadobutrol injections. Administration of the same total amount of gadobutrol over a shorter period caused greater SI increase. KEY POINTS: Gadolinium deposition may occur within the human brain after multiple gadolinium contrast administrations. Increasing T1W signal intensity occurs within the dentate nucleus and globus pallidus. Increasing signal intensity may be a consequence of multiple administrations of gadobutrol. Administration of gadobutrol over a shorter period causes greater signal intensity increase.

Entities:  

Keywords:  Contrast media; Dentate nucleus; Gadolinium deposition; Globus pallidus; Magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26105022     DOI: 10.1007/s00330-015-3879-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  37 in total

1.  Hyperintense basal ganglia on T1-weighted MR imaging.

Authors:  P H Lai; C Chen; H L Liang; H B Pan
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

2.  MR imaging in acute multiple sclerosis: ringlike appearance in plaques suggesting the presence of paramagnetic free radicals.

Authors:  T Powell; J G Sussman; G A Davies-Jones
Journal:  AJNR Am J Neuroradiol       Date:  1992 Nov-Dec       Impact factor: 3.825

3.  Presence of activated microglia in a high-signal lesion on T1-weighted MR images: a biopsy sample re-examined.

Authors:  Din-E Shan; Hung-Chi Pan; Donald M T Ho; Michael M H Teng; Chen Chang
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

4.  Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition.

Authors:  S A Mirowitz; T J Westrich; J D Hirsch
Journal:  Radiology       Date:  1991-10       Impact factor: 11.105

Review 5.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

6.  Magnetic resonance imaging shows delayed ischemic striatal neurodegeneration.

Authors:  Masayuki Fujioka; Toshiaki Taoka; Yoshiyuki Matsuo; Kenichi Mishima; Kumiko Ogoshi; Yoichi Kondo; Masakazu Tsuda; Michihiro Fujiwara; Takao Asano; Toshisuke Sakaki; Akihiro Miyasaki; Darren Park; Bo K Siesjö
Journal:  Ann Neurol       Date:  2003-12       Impact factor: 10.422

7.  Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T.

Authors:  J A Brunberg; E Kanal; W Hirsch; D H Van Thiel
Journal:  AJNR Am J Neuroradiol       Date:  1991 Sep-Oct       Impact factor: 3.825

8.  Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.

Authors:  Gregory W White; Wendell A Gibby; Michael F Tweedle
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

10.  Evolution of high-intensity basal ganglia lesions on T1-weighted MR in neurofibromatosis type 1.

Authors:  H Terada; A J Barkovich; M S Edwards; S M Ciricillo
Journal:  AJNR Am J Neuroradiol       Date:  1996-04       Impact factor: 3.825

View more
  76 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Reply to Letter to the Editor re: Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: Correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol.

Authors:  Dragan A Stojanov
Journal:  Eur Radiol       Date:  2015-09-21       Impact factor: 5.315

3.  Spine MRI in Spontaneous Intracranial Hypotension for CSF Leak Detection: Nonsuperiority of Intrathecal Gadolinium to Heavily T2-Weighted Fat-Saturated Sequences.

Authors:  T Dobrocky; A Winklehner; P S Breiding; L Grunder; G Peschi; L Häni; P J Mosimann; M Branca; J Kaesmacher; P Mordasini; A Raabe; C T Ulrich; J Beck; J Gralla; E I Piechowiak
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-18       Impact factor: 3.825

4.  Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model.

Authors:  Sohi Bae; Ho-Joon Lee; Kyunghwa Han; Yae-Won Park; Yoon Seong Choi; Sung Soo Ahn; Jinna Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2017-01-12       Impact factor: 5.315

5.  Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.

Authors:  Alessandra Splendiani; Marco Perri; Claudia Marsecano; Valentina Vellucci; Giulia Michelini; Antonio Barile; Ernesto Di Cesare
Journal:  Radiol Med       Date:  2017-09-27       Impact factor: 3.469

6.  Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study.

Authors:  Gaetano Perrotta; Thierry Metens; Julie Absil; Marc Lemort; Mario Manto
Journal:  J Neurol       Date:  2017-09-27       Impact factor: 4.849

7.  Signal intensity increases in dentate nucleus/globus pallidus/pulvinar on unenhanced T1WI MR images after multiple examinations with gadodiamide.

Authors:  Takao Koiso; Masaaki Yamamoto; Shinya Watanabe; Bierta E Barfod
Journal:  Neuroradiol J       Date:  2019-03-29

Review 8.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

Review 9.  Gadolinium-based contrast agents in children.

Authors:  Michael N Rozenfeld; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2018-08-04

Review 10.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.